CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients

Eur Neurol. 2022;85(1):69-71. doi: 10.1159/000517770. Epub 2021 Aug 2.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chemokine CXCL13
  • Fingolimod Hydrochloride* / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Multiple Sclerosis* / drug therapy

Substances

  • CXCL13 protein, human
  • Chemokine CXCL13
  • Immunosuppressive Agents
  • Fingolimod Hydrochloride